Subscribers can find out export and import data of 23 countries by HS code or product’s name. This demo is helpful for market analysis.

Subscribers can find out export and import data of 23 countries by HS code or product’s name. This demo is helpful for market analysis.

Market Overview:

The 7 major Usher syndrome type 2 markets reached a value of US$ 1.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1.8 Billion by 2034, exhibiting a growth rate (CAGR) of 3.63% during 2024-2034.

Report Attribute	Key Statistics
Base Year	2023
Forecast Years	2024-2034
Historical Years	2018-2023
Market Size in 2023	US$ 1.2 Billion
Market Forecast in 2034	US$ 1.8 Billion
Market Growth Rate 2024-2034	3.63%

The Usher syndrome type 2 market has been comprehensively analyzed in IMARC's new report titled "Usher Syndrome Type 2 Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Usher syndrome type 2 is a rare genetic disorder characterized by its dual impact on both hearing and vision. In this condition, the hearing loss is congenital and typically moderate to severe, making communication challenging from early childhood. The symptoms of the ailment manifest as a progressive loss of hearing and a gradual onset of vision problems. Individuals suffering from this syndrome may experience difficulties with speech and language development due to their hearing impairment. The visual deterioration is characterized by retinitis pigmentosa, a condition that leads to the degeneration of photoreceptor cells in the retina, causing night blindness and tunnel vision that worsen over time. The diagnosis of Usher syndrome type 2 involves a thorough assessment of both auditory and visual functions to help in determining the extent of hearing loss and the degree of retinal degeneration in patients. Genetic testing plays a crucial role in confirming the diagnosis by identifying mutations in genes associated with the disorder.

https://www.imarcgroup.com/CKEditor/d5666145-c0d7-4e70-87ef-85514eee43f2usher-syndrome-type-2-market.webp" style="height:450px; width:800px" />

The escalating prevalence of mutations in the USH2A gene, which mainly leads to the dual sensory impairment of both hearing and vision, is primarily driving the Usher syndrome type 2 market. In addition to this, the inflating utilization of hearing aids and cochlear implants, supported by advancements in auditory technology, is also creating a positive outlook for the market. These devices aid in mitigating the hearing loss component of the syndrome, thereby enabling better communication and interaction with the surrounding environment. Moreover, the widespread adoption of physical and orientation mobility training to improve spatial awareness and navigation skills in individuals suffering from the ailment is further bolstering the market growth. Apart from this, the rising usage of telemedicine for regular check-ups and consultations, since it offers a more accessible approach to disease management, is acting as another significant growth-inducing factor. Additionally, the increasing application of protein-based interventions that can effectively slow or prevent sensory deterioration in patients is also augmenting the market growth. Furthermore, the emerging popularity of innovative treatments encompassing gene augmentation therapy, which involves introducing functional genetic material to replace or rectify mutated genes, is expected to drive the Usher syndrome type 2 market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Usher syndrome type 2 market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Usher syndrome type 2 and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Usher syndrome type 2 market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
  

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Usher syndrome type 2 market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Usher syndrome type 2 market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current usher syndrome type 2 marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
  

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
  

Drugs	Company Name
NT 501	Neurotech Pharmaceutical
Ultevursen	ProQR Therapeutics

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Usher syndrome type 2 market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the Usher syndrome type 2 market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the Usher syndrome type 2 market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
  

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of Usher syndrome type 2 across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Usher syndrome type 2 by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Usher syndrome type 2 by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with Usher syndrome type 2 across the seven major markets?
• What is the size of the Usher syndrome type 2 patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of Usher syndrome type 2?
• What will be the growth rate of patients across the seven major markets?
  

Usher Syndrome Type 2: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Usher syndrome type 2 drugs across the seven major markets?
• Who are the key companies in

Palm Oil decreased 155 MYR/MT or 3.49% since the beginning of 2025, according to trading on a contract for difference (CFD) that tracks the benchmark market for this commodity. Palm Oil - values, historical data, forecasts and news - updated on March of 2025.